公开(公告)号：US20240358725A1

公开(公告)日：2024-10-31

申请号：US18682693

申请日：2022-08-10

Applicant: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

Inventor： Babak BABAN ,  Jack YU

IPC: A61K31/00 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/658 ,  A61K9/008 ,  A61P35/00

Abstract: A method of reducing tumor size in a subject in need thereof, comprising administering to the subject an effective amount of cannabidiol effective to inhibit tumor growth.

公开(公告)号：US20240316083A1

公开(公告)日：2024-09-26

申请号：US18632745

申请日：2024-04-11

Applicant: MEDIZINISCHE UNIVERSITAT WIEN

Inventor： JOHANNES STOCKL ,  GUIDO GUALDONI

IPC: A61K31/7004 ,  A61K9/00 ,  A61K45/06 ,  A61P31/16

CPC classification number: A61K31/7004 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K45/06 ,  A61P31/16

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

公开(公告)号：US20240316082A1

公开(公告)日：2024-09-26

申请号：US18598608

申请日：2024-03-07

Applicant: MEDIZINISCHE UNIVERSITAT WIEN

Inventor： JOHANNES STOCKL ,  GUIDO GUALDONI

IPC: A61K31/7004 ,  A61K9/00 ,  A61K45/06 ,  A61P31/16

CPC classification number: A61K31/7004 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K45/06 ,  A61P31/16

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

公开(公告)号：US20240307322A1

公开(公告)日：2024-09-19

申请号：US18661125

申请日：2024-05-10

Applicant: Janssen Pharmaceutica NV

Inventor： Jingli Wang ,  Michael Cannamela ,  Hong Yan ,  Rochelle Kleinberg

IPC: A61K31/135 ,  A61K9/00 ,  A61M5/315

CPC classification number: A61K31/135 ,  A61K9/0043 ,  A61K9/008 ,  A61M5/31533

Abstract: The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

公开(公告)号：US12090164B2

公开(公告)日：2024-09-17

申请号：US16754651

申请日：2018-10-11

Applicant: The Board of Trustees of the University of Illinois ,  University of Iowa Research Foundation

Inventor： Martin D. Burke ,  Katrina A. Muraglia ,  Rajeev S. Chorghade ,  Michael J. Welsh

IPC: A61K31/7048 ,  A61K9/00 ,  A61K9/127 ,  A61K31/575 ,  A61P11/00

CPC classification number: A61K31/7048 ,  A61K9/008 ,  A61K9/127 ,  A61K31/575 ,  A61P11/00

Abstract: Disclosed are methods of treating cystic fibrosis using AmB and a sterol or compositions comprising AmB and a sterol. Also disclosed are methods of increasing the pH of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol; and methods of decreasing the viscosity of airway surface liquid in a patient having cystic fibrosis using AmB and a sterol.

公开(公告)号：US20240226006A1

公开(公告)日：2024-07-11

申请号：US18425676

申请日：2024-01-29

Applicant: Covis Pharma GmbH

Inventor： Helgert Müller ,  Renate Engelstätter ,  Ulrich Bildmann ,  Andrea Bauer ,  Paul McGlynn

IPC: A61K9/12 ,  A61K9/00 ,  A61K31/58 ,  A61M11/04 ,  A61M15/00

CPC classification number: A61K9/124 ,  A61K9/008 ,  A61K31/58 ,  A61M11/04 ,  A61M15/0001 ,  A61M15/0065 ,  A61M15/009

Abstract: This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1,1,1,2-tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoropropane.

公开(公告)号：US12011453B2

公开(公告)日：2024-06-18

申请号：US17811488

申请日：2022-07-08

Applicant: MEDIZINISCHE UNIVERSITAT WIEN

Inventor： Johannes Stockl ,  Guido Gualdoni

IPC: A61K31/7004 ,  A61K9/00 ,  A61K45/06 ,  A61P31/16

CPC classification number: A61K31/7004 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K45/06 ,  A61P31/16

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

公开(公告)号：US11992553B2

公开(公告)日：2024-05-28

申请号：US17445577

申请日：2021-08-20

Applicant: AlgiPharma AS

Inventor： Bildad Nyambura ,  Anand Bakle ,  Arne Dessen

IPC: A61K9/16 ,  A61K9/00 ,  A61K9/48 ,  A61P11/00

CPC classification number: A61K9/0075 ,  A61K9/008 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/4808 ,  A61P11/00

Abstract: A method of preparing spray dried particles for inhalation comprising providing: (i) an aqueous liquid composition including the alginate oligomer and an aqueous liquid composition including an anti-adherent compound, or (ii) an aqueous liquid composition including the alginate oligomer and an anti-adherent compound; providing an organic liquid composition including a phospholipid; combining a volume of the organic liquid composition with a volume of the aqueous liquid composition, wherein the total volume of the organic liquid composition is smaller than the total volume of the aqueous liquid composition with which it is combined, and wherein the total volume of aqueous liquid composition and said total volume of organic liquid composition are sufficient to provide a combination; homogenizing the combination to form an organic-in-aqueous liquid emulsion for spray drying; and spray drying the organic-in-aqueous liquid emulsion to form the spray dried particles for inhalation.

公开(公告)号：US20240084306A1

公开(公告)日：2024-03-14

申请号：US18330588

申请日：2023-06-07

Applicant: Onspira Therapeutics, Inc.

Inventor： Roy C. LEVITT, JR.

IPC: C12N15/113 ,  A61K9/00 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/17 ,  A61K38/20 ,  A61K39/395 ,  A61K45/06 ,  A61P11/08 ,  C07K14/715

CPC classification number: C12N15/1136 ,  A61K9/007 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/008 ,  A61K31/70 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2006 ,  A61K39/3955 ,  A61K45/06 ,  A61P11/08 ,  C07K14/7155 ,  C12N15/113 ,  C07K2319/30 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30

Abstract: The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.

公开(公告)号：US20240033286A1

公开(公告)日：2024-02-01

申请号：US18179283

申请日：2023-03-06

Applicant: I2PURE CORP.

Inventor： Jack KESSLER ,  David C. LITZINGER ,  Christopher RHODES ,  Andrew M. CERRO

IPC: A61K33/18 ,  A61P31/04 ,  A61K9/00 ,  A61K9/06 ,  A61K47/10

CPC classification number: A61K33/18 ,  A61P31/04 ,  A61K9/0043 ,  A61K9/008 ,  A61K9/06 ,  A61K47/10

Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.